An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum
Editorial by Prof Manolis Tsiknakis, Coordinator of ProCAncer-I project The ProCAncer-I project has completed the first year of its lifecycle at the end of October 2021. With this brief note key results and achievements of the first year are summarized in the sequel....
Within the ProCancer-I project, a total of nine clinical needs will be addressed utilizing artificial intelligence (AI) models trained on ProstateNET – a unified repository of 1.5 million images of prostate MRI acquired across the consortium. In the current landscape...
ProCAncer-I aspires to create the largest interoperable, high-quality multi-parametric Magnetic Resonance Imaging (mpMRI) dataset worldwide/globally comprising more than 11.000 retrospective and more than 6.000 prospective mpMRI examinations, including clinical data,...
Interview with prof. Daniele Regge (Clinical Coordinator of the ProCancer-I project) Q: In the case of prostate cancer there are several tests that can help clinicians in the decision process, for example, prediction algorithms based on PSA blood test and biopsy. Why...
A brief historical survey of European state-of-play, the open issues and the ProCAncer-I approach Over the last decade, Artificial Intelligence (AI) solutions to support the whole value-chain of medical imaging[1] has experienced a considerable acceleration. This...
By the Fundacao D. Anna Sommer Champalimaud e Dr. Carloss Montez Champalimaud (CF) Champalimaud Foundation (CF) is a private non-profit Portuguese institution, inaugurated in 2010 with the aim of advancing basic and translational world-leading research in...
By the FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE) The FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA (HULAFE) is a Spanish non-profit organization that carries out...
By the Massachusetts General Hospital (The General Hospital Corp) (QTIM) Our lab, the Quantitative Translational Imaging in Medicine (QTIM) lab, at the Athinoula A. Martinos Center for Biomedical Imaging of the Massachusetts General Hospital (MGH), focuses on...
Newsletter #2 Contents
ProCAncer-I is part of the European Federation for Cancer Images (EUCAIM) project and the European Cancer Imaging Initiative
The Commission is organising a hybrid event on 23 January 2023 in Brussels to mark the launch of the Cancer Imaging Initiative, one of the Flagship Initiatives of the Europe’s Beating Cancer Plan. This 2.5-hour event will present the policy background and the Cancer...
The ProCAncer-I project participated at the “Current Developments in Radiology” conference, organized by the Hellenic Radiological Society. The conference was held on December 09-11, 2022 in Athens, Greece at Divani Caravel Hotel. During the Conference, which was...
Our Scientific Manager, Dr Nickolas Papanikolaou was at the 108th Scientific Assembly and Annual meeting (Chicago 27-30/11/2022). The panel discussion included Dr Mona Flores, Global Head of Medical AI at NVIDIA, and Dr Nikos Papanikolaou, Computational Clinical...
The #EUCAIM project originates from the work and expertise of the AI for Health Imaging Network (AI4HI), composed of INCISIVE, @chaimeleon_eu, @EuCanImage, @ProCAncer_I and @primage_project. #EUCancerImaging #DigitalEU #EUCancerPlan https://digital-strategy.ec.europa.eu/en/policies/cancer-imaging
Proud to be part of the #EUCAIM project led by @EIBIR_biomed, supporting the #EUCancerImaging Initiative by contributing to an infrastructure of Cancer #images and development & benchmarking of AI tools with #EuroBioImaging Nodes & many other partners.
https://www.eurobioimaging.eu/news/proud-to-be-part-of-the-eucaim-project-/
The launch of #EUCancerImaging Initiative will boost innovative cancer diagnostics and treatment and make screening more precise and accessible.
It shows the potential of digital solutions that can bring hope to cancer patients and their families.
#EUCancerPlan
